Skip to content
Back to EWTX

Edgewise Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
18
Purchases
0
Sales
18
Purchase value
$0.00
Sale value
$16.52M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Joanne M. DonovanCMO
4Rule 10b5-1 plan disclosed
Filed Nov 18, 2026Period of report Nov 16, 20260001644087-26-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 16, 2026
Common StockF1F2854$45.48$38.84K8,139Direct
Filing footnotes · 2
  1. F1The shares were acquired through a purchase under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2025.
  2. F2Includes 368 shares purchased on November 16, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
Open on SEC EDGAR
Michael NofiChief Financial Officer
4
Filed Nov 10, 2026Period of report Nov 10, 20260001705477-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF1F24,442$45.427$201.79K6,495Direct
Filing footnotes · 3
  1. F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.
Open on SEC EDGAR
Kevin KochDirector · President and CEO
4
Filed Aug 14, 2026Period of report Aug 12, 20260001185829-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 12, 2026
Common StockF1F28,782$43.6408$383.25K61,677Direct
SaleAug 12, 2026
Common StockF1F38,276$43.6582$361.32K53,401Direct
SaleAug 12, 2026
Common StockF1F4913$44.33$40.47K52,488Direct
Filing footnotes · 8
  1. F1Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
  6. F6Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
  7. F7Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
  8. F81/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Open on SEC EDGAR
Alan J RussellDirector · Chief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 2, 2026Period of report Jul 1, 20260001853529-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF2130,352$39.406$5.14M94,203Direct
SaleJul 1, 2026
Common StockF369,648$39.4089$2.74M24,555Direct
Filing footnotes · 5
  1. F1Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F41/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date.
  5. F51/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date.
Open on SEC EDGAR
Joanne M. DonovanCMO
4
Filed May 5, 2026Period of report May 4, 20260001644087-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 5, 2026
Common StockF1F350,000$38.568$1.93M4,367Direct
SaleMay 4, 2026
Common StockF1F25,230$31.2931$163.66K4,367Direct
Filing footnotes · 4
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F41/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Open on SEC EDGAR
Joanne M. DonovanCMO
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Apr 1, 20260001644087-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 1, 2026
Common StockF1F228,662$32.3109$926.10K9,597Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F31/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Open on SEC EDGAR
Joanne M. DonovanCMO
4Rule 10b5-1 plan disclosed
Filed Mar 31, 2026Period of report Mar 31, 20260001644087-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 31, 2026
Common StockF1F221,338$32.1168$685.31K9,597Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F31/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.
Open on SEC EDGAR
Joanne M. DonovanCMO
4Rule 10b5-1 plan disclosed
Filed Mar 30, 2026Period of report Mar 27, 20260001644087-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 27, 2026
Common StockF1F2F39,623$30.9778$298.10K16,332Direct
SaleMar 27, 2026
Common StockF26,735$30.9778$208.64K9,597Direct
Filing footnotes · 3
  1. F1The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares).
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
Open on SEC EDGAR
Badreddin EdrisDirector
4Rule 10b5-1 plan disclosed
Filed Jan 23, 2026Period of report Jan 21, 20260001786966-26-000001
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 21, 2026
Common StockF1F213,690$29.44$403.03K121,601Direct
SaleJan 21, 2026
Common StockF1F217,236$29.44$507.43K104,365Direct
SaleJan 21, 2026
Common StockF1F27,605$29.44$223.89K96,760Direct
SaleJan 21, 2026
Common StockF1F210,463$29.44$308.03K86,297Direct
SaleJan 21, 2026
Common StockF1F266,477$29.44$1.96M19,820Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025.
  2. F2The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.